Hepatic steatosis-insulin resistance and type 2 diabetes in people with HIV at diagnosis: effect of initial antiretroviral therapy

被引：0

作者：

Montes, Maria Luisa ^{[1
,2
]}

Busca, Carmen ^{[1
,2
]}

Rava, Marta ^{[2
,3
]}

Bernardino, Jose Ignacio ^{[1
,2
]}

Rivero, Antonio ^{[2
,4
]}

Martin-Carbonero, Luz ^{[1
,2
]}

Canas-Ruano, Esperanza ^{[2
,5
]}

Ugarte, Sofia Ibarra ^{[6
]}

Galindo, Maria Jose ^{[7
]}

Cabello, Alfonso ^{[8
]}

Gonzalez-Garcia, Juan ^{[1
,2
]}

机构：

[1] Hosp Univ La Paz, Inst Hlth Res IdiPAZ, Serv Med Interna, Unidad VIH, Madrid, Spain

[2] Inst Salud Carlos III, Ctr Biomed Res Infect Dis CIBERINFEC CB21 13 00091, Madrid, Spain

[3] Carlos III Hlth Inst, Natl Ctr Epidemiol, Madrid, Spain

[4] Univ Cordoba UCO, Hosp Univ Reina Sofia, Dept Infect Dis, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Argentina

[5] Hosp Mar, Dept Infect Dis, Inst Hosp Mar Med Res IMIM, Barcelona 08003, Spain

[6] Hosp Univ Basurto, Serv Enfermedades Infecciosas, Bilbao, Bizkaia, Spain

[7] Hosp Clin Univ Valencia, Valencia, Spain

[8] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

来源：

AIDS | 2024年 / 38卷 / 14期

关键词：

FIBROSIS;

D O I：

10.1097/QAD.0000000000004008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated the impact of hepatic steatosis-insulin resistance (HS-IR) and liver fibrosis (LF) on type 2 diabetes mellitus (DM2) using triglyceride-glucose (TyG) and Fibrosis-4 (FIB-4). The incidence of DM2 was 12.9 [95% confidence interval (CI), 16.9-9.7] and 9.8 (95% CI, 6.9-13.6) per 1000 person-years in HS-IR and LF. The prevalence of HS-IR was significantly lower at 12 and 24 months with TDF + (3TC or FTC) + RPV [hazard ratio (HR) 0.5 [95% CI, 0.3-0.8], P < 0.01 at 12 months; 0.6 [0.4-0.9], P = 0.01 at 24 months].

引用

页码：1982 / 1987

页数：6

共 50 条

[21] Importance of insulin therapy in people with type 2 diabetes mellitus
Jecht, Michael
Doetsch, Iris
Haeussler, Ralf-Uwe
DIABETOLOGIE, 2024, 20 (08): : 904 - 910
[22] Easing the transition to insulin therapy in people with type 2 diabetes
Blonde, Lawrence
DIABETES EDUCATOR, 2007, 33 : 232S - 240S
[23] Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors
Bratt, Goran
Brannstrom, Johanna
Missalidis, Catharina
Nystrom, Thomas
PLOS ONE, 2021, 16 (06):
[24] Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis
Mohr, Raphael
Boesecke, Christoph
Dold, Leona
Schierwagen, Robert
Schwarze-Zander, Carolynne
Wasmuth, Jan-Christian
Weisensee, Insa
Rockstroh, Juergen Kurt
Trebicka, Jonel
MEDICINE, 2018, 97 (17)
[25] Defective Hepatic Energy Homeostasis Predicts Hepatic Insulin Resistance in Type 2 Diabetes
Szendroedi, Julia
Chmelik, Marek
Schmid, Albrecht I.
Nowotny, Peter
Brehm, Attila
Krssak, Martin
Moser, Ewald
Roden, Michael
DIABETES, 2009, 58 : A382 - A382
[26] Neuregulin 4 could be a new serum marker of insulin resistance, diabetes and lipid disorders development in people living with HIV on suppressive antiretroviral therapy
Sapula, M.
Suchacz, M.
Wiercinska-Drapalo, A.
HIV MEDICINE, 2023, 24 : 286 - 287
[27] Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
Kjeldsen, Sasha A. S.
Thomsen, Mads N.
Skytte, Mads J.
Samkani, Amirsalar
Richter, Michael M.
Frystyk, Jan
Magkos, Faidon
Hansen, Elizaveta
Thomsen, Henrik S.
Holst, Jens J.
Madsbad, Sten
Haugaard, Steen B.
Krarup, Thure
Albrechtsen, Nicolai J. Wewer
JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (11)
[28] Insulin resistance at diagnosis in Japanese children with type 2 diabetes mellitus
Urakami, Tatsuhiko
Habu, Masako
Kuwabara, Remi
Komiya, Kei
Nagano, Nobuhiko
Suzuki, Junichi
Mugishima, Hideo
PEDIATRICS INTERNATIONAL, 2012, 54 (04) : 516 - 519
[29] Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD
Koshino, Akihiko
Oshima, Megumi
Arnott, Clare G.
Fletcher, Robert A.
Perkovic, Vlado
Heerspink, Hiddo J. L.
Neuen, Brendon L.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 673 - 674
[30] Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
Lavynenko, Olga
Abdul-Ghani, Muhammad
Alatrach, Mariam
Puckett, Curtiss
Adams, John
Abdelgani, Siham
Alkhouri, Naim
Triplitt, Curtis
Clarke, Geoffrey D.
Vasquez, Juan A.
Li, Jinqi
Cersosimo, Eugenio
Gastaldelli, Amalia
DeFronzo, Ralph A.
DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 899 - 907

← 1 2 3 4 5 →